...
首页> 外文期刊>Open Forum Infectious Diseases >Epidemiology and Risk Factors for Echinocandin Nonsusceptible Candida glabrata Bloodstream Infections: Data From a Large Multisite Population-Based Candidemia Surveillance Program, 2008–2014
【24h】

Epidemiology and Risk Factors for Echinocandin Nonsusceptible Candida glabrata Bloodstream Infections: Data From a Large Multisite Population-Based Candidemia Surveillance Program, 2008–2014

机译:Echinocandin不易感的光滑念珠菌血流感染的流行病学和危险因素:基于大型多站点人群的念珠菌病监测计划的数据,2008-2014年

获取原文
           

摘要

Background.?Echinocandins are first-line treatment for Candida glabrata candidemia. Echinocandin resistance is concerning due to limited remaining treatment options. We used data from a multisite, population-based surveillance program to describe the epidemiology and risk factors for echinocandin nonsusceptible (NS) C glabrata candidemia. Methods.?The Centers for Disease Control and Prevention's Emerging Infections Program conducts population-based laboratory surveillance for candidemia in 4 metropolitan areas (7.9 million persons; 80 hospitals). We identified C glabrata cases occurring during 2008–2014; medical records of cases were reviewed, and C glabrata isolates underwent broth microdilution antifungal susceptibility testing. We defined echinocandin-NS C glabrata (intermediate or resistant) based on 2012 Clinical and Laboratory Standards Institute minimum inhibitory concentration breakpoints. Independent risk factors for NS C glabrata were determined by stepwise logistic regression. Results.?Of 1385 C glabrata cases, 83 (6.0%) had NS isolates (19 intermediate and 64 resistant); the proportion of NS isolates rose from 4.2% in 2008 to 7.8% in 2014 (P .001). The proportion of NS isolates at each hospital ranged from 0% to 25.8%; 3 large, academic hospitals accounted for almost half of all NS isolates. In multivariate analysis, prior echinocandin exposure (adjusted odds ratio [aOR], 5.3; 95% CI, 2.6–1.2), previous candidemia episode (aOR, 2.5; 95% CI, 1.2–5.1), hospitalization in the last 90 days (aOR, 1.9; 95% CI, 1.0–3.5, and fluconazole resistance [aOR, 3.6; 95% CI, 2.0–6.4]) were significantly associated with NS C glabrata. Fifty-nine percent of NS C glabrata cases had no known prior echinocandin exposure. Conclusion.?The proportion of NS C glabrata isolates rose significantly during 2008–2014, and NS C glabrata frequency differed across hospitals. In addition to acquired resistance resulting from prior drug exposure, occurrence of NS C glabrata without prior echinocandin exposure suggests possible transmission of resistant organisms.
机译:背景:棘球and素是光滑念珠菌念珠菌血症的一线治疗。由于剩余的治疗选择有限,因此对棘球and霉素的耐药性令人担忧。我们使用了来自多站点,基于人群的监视程序中的数据,来描述棘皮棘皮病不敏感(C)光滑念珠菌念珠菌血症的流行病学和危险因素。方法:疾病控制和预防中心的新发感染项目在4个大城市地区(790万人口; 80所医院)进行了基于人群的念珠菌病实验室监测。我们确定了在2008–2014年间发生的C glabrata病例。对病例的病历进行了回顾,并对光滑无芒草分离物进行了肉汤微稀释抗真菌药敏试验。我们根据2012年临床和实验室标准协会的最低抑菌浓度断点定义棘球菌素-NS C glabrata(中度或耐药)。通过逐步逻辑回归确定NS C光滑的独立危险因素。结果:在1385例光滑毛C病病例中,有83例(6.0%)具有NS分离株(19例中度和64例耐药); NS分离株的比例从2008年的4.2%上升到2014年的7.8%(P <.001)。每家医院的NS分离株比例在0%至25.8%之间。 3家大型的学术医院几乎占所有NS分离株的一半。在多变量分析中,先前棘皮菌素暴露(校正比值比[aOR],5.3; 95%CI,2.6-1.2),先前的念珠菌血症发作(aOR,2.5; 95%CI,1.2-5.1),最近90天内住院( aOR,1.9; 95%CI,1.0-3.5,和氟康唑耐药性[aOR,3.6; 95%CI,2.0-6.4])与NS C光滑毛虫显着相关。 59%的NS C glabrata病例之前没有已知棘皮菌素暴露。结论:2008年至2014年间,NSC glabrata分离株的比例显着上升,并且各家医院的NS C glabrata频率有所不同。除因先前接触药物而获得的耐药性外,未事先与棘皮菌素接触而出现的NS C glabrata也表明可能传播了耐药生物。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号